Product Name: Lincomycin hydrochloride injection
Nombre del Producto: Lincomicina solución inyectable
Package: 10amps/box, 50amps/box, 100amps/box
Standard: USP & BP & CP
Its solutions are acid and are dextrorotatory. Lincomycin hydrochloride injectionis freely soluble in water, soluble in dimethylformamide and very slightly soluble in acetone.
Lincomycin hydrochloride injectionInjection is a clear, colourless or almost colourless solution, practically free from particles.
Dosage and administration
Note: If significant diarrhoea occurs during therapy, this antibiotic should be discontinued .
Lincomycin hydrochloride injectionis incompatible with novobiocin, kanamycin and phenytoin.
With beta-haemolytic streptococcal infections, treatment should continue for at least 10 days to diminish the likelihood of subsequent rheumatic fever or glomerulonephritis.
Serious infections - 600 mg (2 mL) intramuscularly every 24 hours.
More serious infections - 600 mg (2 mL) intramuscularly every 12 hours or more often, as determined by the severity of the infection.
Children over 1 month of age:
Serious infections - one intramuscular injection of 10 mg/kg/day.
More serious infections - one intramuscular injection of 10 mg/kg every 12 hours or more often.
Intravenous doses are given on the basis of 1 g Lincomycin hydrochloride injectiondiluted in not less than 100 mL of appropriate solution and infused over a period of not less than one hour. Note: Severe cardiopulmonary reactions have occurred when this drug has been given at greater than the recommended concentration and rate.
Serious infections - 600 mg to 1 g given every 8-12 hours.
More severe infections - the above doses may be increased. In life-threatening situations, daily intravenous doses of as much as 8 g have been given.
Children over 1 month of age:
Depending on the severity of the infection, 10-20 mg/kg/day may be infused in divided doses as described in the table below.
Lincomycin hydrochloride injectionis indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.
Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. Because of the risk of colitis, before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).
Lincomycin hydrochloride injectionhas been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. Staphylococcal strains resistant to Lincomycin hydrochloride injectionhave been recovered; culture and susceptibility studies should be done in conjunction with Lincomycin hydrochloride injectiontherapy. In the case of macrolides, partial but not complete cross resistance may occur. The drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated.
The specific infections for which Lincomycin hydrochloride injectionis indicated are as follows:
* Upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. Effectiveness in the treatment of mastoiditis would be anticipated.
* Lower respiratory infections including acute and chronic bronchitis and pneumonia.
* Skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. Conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.
* Bone and joint infections including osteomyelitis and septic arthritis.
* Septicaemia and endocarditis. Selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. However, bactericidal drugs are often preferred for these infections.
* Bacillary Dysentery. Although Shigella is resistant to lincomycin in vitro (MIC approximately 200-400 micrograms/mL), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).
This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin. It is not indicated in the treatment of minor bacterial infections or viral infections.
Lincomycin is not indicated in the newborn.
Interactions with other medicines
Lincomycin hydrochloride injectionhas been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
Antagonism has been demonstrated between lincomycin and erythromycin in vitro. Because of possible clinical significance, these two drugs should not be administered concurrently.
Related Keywords: We are considered as one of the leading manufacturers and suppliers of lincomycin injection. With the aid of our technologically advanced manufacturing section, we are able to offer customers lincomycin injection products which are tested on various quality parameters in order to supply flawless range at the customers' end.